774 related articles for article (PubMed ID: 19479704)
1. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
Polinski JM; Mohr PE; Johnson L
Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
[TBL] [Abstract][Full Text] [Related]
2. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
[TBL] [Abstract][Full Text] [Related]
3. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
4. Specialty Tier-Level Cost Sharing and Biologic Agent Use in the Medicare Part D Initial Coverage Period Among Beneficiaries With Rheumatoid Arthritis.
Doshi JA; Hu T; Li P; Pettit AR; Yu X; Blum M
Arthritis Care Res (Hoboken); 2016 Nov; 68(11):1624-1630. PubMed ID: 27014854
[TBL] [Abstract][Full Text] [Related]
5. Use and Spending for Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries.
Yazdany J; Tonner C; Schmajuk G
Arthritis Care Res (Hoboken); 2015 Sep; 67(9):1210-1218. PubMed ID: 25776035
[TBL] [Abstract][Full Text] [Related]
6. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
Patel UD; Davis MM
J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
[TBL] [Abstract][Full Text] [Related]
7. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
[TBL] [Abstract][Full Text] [Related]
8. 2007 costs and coverage of antiretrovirals under Medicare Part D for people with HIV/AIDS living in North Carolina.
Sengupta S
N C Med J; 2008; 69(1):6-13. PubMed ID: 18429558
[TBL] [Abstract][Full Text] [Related]
9. Cost minimization of medicare part D prescription drug plan expenditures.
Patel RA; Lipton HL; Cutler TW; Smith AR; Tsunoda SM; Stebbins MR
Am J Manag Care; 2009 Aug; 15(8):545-53. PubMed ID: 19670958
[TBL] [Abstract][Full Text] [Related]
10. Medicare Part D: successes and continuing challenges. Impact of Medicare Part D on Massachusetts health programs and beneficiaries.
Thomas CP; Sussman J; ;
Issue Brief (Mass Health Policy Forum); 2007 May; (32):1-32. PubMed ID: 17546802
[TBL] [Abstract][Full Text] [Related]
11. Understanding the Medicare Part D prescription program: partnerships for beneficiaries and health care professionals.
De Natale ML
Policy Polit Nurs Pract; 2007 Aug; 8(3):170-81. PubMed ID: 18178923
[TBL] [Abstract][Full Text] [Related]
12. Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006.
Bowman J; Rousseau A; Silk D; Harrison C
Health Aff (Millwood); 2006; 25(5):1240-8. PubMed ID: 16966719
[TBL] [Abstract][Full Text] [Related]
13. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal.
Schmajuk G; Schneeweiss S; Katz JN; Weinblatt ME; Setoguchi S; Avorn J; Levin R; Solomon DH
Arthritis Rheum; 2007 Aug; 57(6):928-34. PubMed ID: 17665462
[TBL] [Abstract][Full Text] [Related]
14. Medicare beneficiary out-of-pocket costs: are Medicare Advantage Plans a better deal?
Biles B; Hersch Nicholas L; Guterman Stuart S
Issue Brief (Commonw Fund); 2006 May; 19():1-16. PubMed ID: 16733884
[TBL] [Abstract][Full Text] [Related]
15. The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of medicare part D: analysis of claims data from the medicare current beneficiary survey.
Lundy J; Craig BM
Clin Ther; 2006 Jan; 28(1):140-5. PubMed ID: 16490588
[TBL] [Abstract][Full Text] [Related]
16. The growing cohort of seniors with HIV/AIDS: changing the scope of Medicare Part D.
Flaer PJ; Benjamin PL; Malow RM; Morisky DE; Parkash J
AIDS Care; 2010 Jul; 22(7):903-8. PubMed ID: 20635255
[TBL] [Abstract][Full Text] [Related]
17. Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis.
Tseng CW; Dudley RA; Chen R; Walensky RP
JAMA Netw Open; 2020 Apr; 3(4):e202739. PubMed ID: 32286656
[TBL] [Abstract][Full Text] [Related]
18. Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis.
Karaca-Mandic P; Joyce GF; Goldman DP; Laouri M
Health Serv Res; 2010 Oct; 45(5 Pt 1):1227-50. PubMed ID: 20831715
[TBL] [Abstract][Full Text] [Related]
19. Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage.
Cubanski J; Neuman P
Health Aff (Millwood); 2007; 26(1):w1-12. PubMed ID: 17118944
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.
Solomon DH; Avorn J; Katz JN; Weinblatt ME; Setoguchi S; Levin R; Schneeweiss S
Arthritis Rheum; 2006 Dec; 54(12):3790-8. PubMed ID: 17136752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]